Top-News
Werbung
Attraktive Knock-Outs auf Viatris Inc
Typ Hebel Bid / Ask WKN
Call
2,3 4,01 € / 4,12 €
SU0UF7
Typ Hebel Bid / Ask WKN
Put
3,4 2,69 € / 2,80 €
SU5YP3
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Viatris Inc

Viatris Aktie News

Aktie
WKN:  A2QAME ISIN:  US92556V1061 US-Symbol:  VTRS Branche:  Pharmazeutika Land:  USA
9,212 €
-0,034 €
-0,37%
14:23:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
10,79 Mrd. €
Streubesitz
14,45%
KGV
-23,49
Dividende
0,12 $
Dividendenrendite
1,12%
neu: Nachhaltigkeits-Score
42 %
Index-Zuordnung
S&P 500

Viatris News

24.11.25 - PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences PR Newswire
19.11.25 - PR Newswire
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und ...
19.11.25 - PR Newswire
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for ...
13.11.25 - PR Newswire
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025 PR Newswire
06.11.25 - PR Newswire
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PR Newswire
04.11.25 - PR Newswire
Viatris Announces Quarterly Dividend
Viatris Announces Quarterly Dividend PR Newswire
15.10.25 - PR Newswire
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-​Pacific Region PR ...
13.10.25 - PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences PR Newswire
08.10.25 - PR Newswire
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row PR Newswire
01.10.25 - PR Newswire
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire
30.08.25 - wallstreetONLINE Redaktion
Börsen-Nieten im Fokus: Diese 10 S&P-500-Aktien haben ein Jahrzehnt lang nur enttäuscht – bis jetzt!
Langfristige Verluste sind im S&P 500 eine Seltenheit – doch zehn Aktien haben in den vergangenen zehn Jahren klar enttäuscht. Welche dieser Nachzügler jetzt mit starken ...
19.08.25 - PR Newswire
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer PR Newswire
11.08.25 - PR Newswire
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. PR Newswire
07.08.25 - PR Newswire
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance PR Newswire
05.08.25 - PR Newswire
Viatris Announces Quarterly Dividend
Viatris Announces Quarterly Dividend PR Newswire
05.08.25 - PR Newswire
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
Viatris Announces Appointment of David Simmons to the Company's Board of Directors PR Newswire
01.08.25 - PR Newswire
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Viatris Announces Five Data Presentations on Novel Fast-​Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference PR Newswire
18.07.25 - PR Newswire
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis PR Newswire
26.06.25 - PR Newswire
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia PR Newswire
12.06.25 - PR Newswire
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025 PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »